83 results about "Therapy intervention" patented technology

A novel approach to diagnostic and therapeutic interventions in the peritoneal cavity is described. More specifically, a technique for accessing the peritoneal cavity via the wall of the digestive tract is provided so that examination of and / or a surgical procedure in the peritoneal cavity can be conducted via the wall of the digestive tract with the use of a flexible endoscope. As presently proposed, the technique is particularly adapted to transgastric peritoneoscopy. However, access in addition or in the alternative through the intestinal wall is contemplated and described as well. Transgastric and / or transintestinal peritoneoscopy will have an excellent cosmetic result as there are no incisions in the abdominal wall and no potential for visible post-surgical scars or hernias.

A novel approach to diagnostic and therapeutic interventions in the peritoneal cavity is described. More specifically, a technique for accessing the peritoneal cavity via the wall of the digestive tract is provided so that examination of and / or a surgical procedure in the peritoneal cavity can be conducted via the wall of the digestive tract with the use of a flexible endoscope. As presently proposed, the technique is particularly adapted to transgastric peritoneoscopy. However, access in addition or in the alternative through the intestinal wall is contemplated and described as well. Transgastric and / or transintestinal peritoneoscopy will have an excellent cosmetic result as there are no incisions in the abdominal wall and no potential for visible post-surgical scars or hernias.

Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and / or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Additionally, serum autoantibody and / or cytokine signature patterns can be utilized to monitor responses to therapy. Assessment of this signature pattern of autoantibodies and / or cytokines in a patient thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is rheumatoid arthritis.

A novel approach to diagnostic and therapeutic interventions in the peritoneal cavity is described. More specifically, a technique for accessing the peritoneal cavity via the wall of the digestive tract is provided so that examination of and / or a surgical procedure in the peritoneal cavity can be conducted via the wall of the digestive tract with the use of a flexible endoscope. As presently proposed, the technique is particularly adapted to transgastric peritoneoscopy. However, access in addition or in the alternative through the intestinal wall is contemplated and described as well. Transgastric and / or transintestinal peritoneoscopy will have an excellent cosmetic result as there are no incisions in the abdominal wall and no potential for visible post-surgical scars or hernias.

Devices and methods for measuring body fluid-related metric using spectrophotometry that may be used to facilitate diagnosis and therapeutic interventions aimed at restoring body fluid balance. In one embodiment, the present invention provides a device for measuring a body-tissue water content metric as a fraction of the fat-free tissue content of a patient using optical spectrophotometry. The device includes a probe housing configured to be placed near a tissue location which is being monitored; light emission optics connected to the housing and configured to direct radiation at the tissue location; light detection optics connected to the housing and configured to receive radiation from the tissue location; and a processing device configured to process radiation from the light emission optics and the light detection optics to compute the metric where the metric includes a ratio of the water content of a portion of patient's tissue in relation to the lean or fat-free content of a portion of patient's tissue.

The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor cells exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and / or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.

The present invention relates to biochemical methods for assessing metabolic fitness and / or aerobic demands of a living system. Specifically, the rate of synthesis and turnover of the molecular components of mitochondrial mass are used to determine the aerobic capacity and / or aerobic demand of tissues or living organisms. The direct measurement of metabolic fitness and / or aerobic demand by this means can be used as an index of the efficacy of an exercise training program or other therapeutic intervention; as a medical risk factor for predicting the risk of cardiovascular disease, diabetes, death or other health outcome; or as an aid to pharmaceutical companies for drug discovery in the area of metabolic fitness, deconditioning, and oxidative biology.

Described herein are methods and systems to measure dynamics of disease progression, including cancer growth and response, at multiple scales by multiple techniques on the same biologic system. Methods and systems according to the invention permit personalized virtual disease models. Moreover, the invention allows for the integration of previously unconnected data points into an in silico disease model, providing for the prediction of disease progression with and without therapeutic intervention.

The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

This invention is a continuous monitor of the spinal cord and brain microenvironment in injury and disease that also allows therapeutic interventions. It utilizes a multiport catheter that contains a transducer at the tip for monitoring spinal physiological parameters and also allows via additional ports for sampling and exchange of spinal fluid, as well as drug delivery to the central nervous system. This invention allows for more precise therapeutic interventions in spinal cord and brain injury and disease. If the pressure monitor is mounted to the patient, the wireless data transmitter may also send a wireless signal to a wireless data receiver for display on a wireless data display. The catheter would allow for wireless transmission of physiological parameters.

A method for diagnosing and treating sleep disorders with a sleep therapy auto-titrator for in-home use by the patient includes the step of collecting, recording and analyzing sleep data in real time with the auto-titrator. Corrective action is provided in real time to the patient to mitigate sleep events based upon the collected sleep data. The collected sleep data is transmitted, via a global computer information system, to a remote server for storage. The stored sleep data is analyzed by a computer programmed with an algorithm to monitor therapy effectiveness daily and for identifying one or more therapy intervention recommendations. An alert is provided to at least one of the patient or a sleep therapy professional associated with the patient communicating the one or more intervention recommendations.

The present disclosure is directed to screening, diagnosing and treating patients having, or suspected of having, rheumatoid arthritis. Levels of glucose-6-phophate isomerase or antibodies to glucose-6-phophate isomerase are assayed in test subjects or populations to determine susceptibility to, or existence of, an antibody mediated form of rheumatoid arthritis in such test subjects or populations. The results of the assays provide guidelines for therapeutic intervention with complement inhibiting agents.

The present invention relates in general to the discovery of urinary succinate as a novel biomarker of kidney disease. More specifically, the invention provides for the measurement of succinate in urine samples that has great potential for the easy and early diagnosis of kidney damage and would allow early prediction of kidney disease and therapeutic intervention.

In a subject undergoing therapeutic intervention, efficacy of the therapeutic intervention is assessed based on a series of physiologic data associated with the subject. The series of physiologic data is analyzed to produce a measure of complexity. The complexity measure is then compared to a control. The efficacy of the therapeutic intervention is assessed based on the comparison of the complexity measure to the control. The control may be, for example, a complexity measure taken prior to initiation of the therapeutic intervention, a complexity measure taken from a different subject, or a predetermined threshold value. The measure of complexity is generated using, for example, a multiscale entropy measurement (MSE), a time asymmetry measurement, and / or an information-based similarity measurement. An increase in complexity indicates a positive effect of the therapeutic intervention, while a decrease in complexity indicates a negative effect of the therapeutic intervention.

In general, the invention features methods for identifying therapeutic interventions for functional illnesses, e.g., neuropathic pain or depression, and methods for identifying markers for functional illnesses by employing an acute painful stimulus or other stimulus for a functional illness and measuring levels of CNS activity.

A computer implemented method, apparatus, and computer program product for determining the efficacy of neuropsychiatric therapy is provided. A neuroimage mapping manager automatically compares a first set of regions of interest in a first set of scans taken at a first time to a second set of regions of interest in a second set of scans generated at a second time and identifies a set of changes in the regions of interest occurring over time. The neuroimage mapping manager searches a set of electronic medical literature sources for medical literature relevant to the set of changes in the regions of interest and identifies portions of the relevant medical literature associated with the set of changes in the regions of interest. The neuroimage mapping manager generates results comprising the set of changes in the regions of interest and a set of links to the portions of the relevant medical literature.

Y receptor agonists which are selective for Y2 and Y4 receptors over the Y1 receptor are useful for treatment of, for example obesity, are (a) PP-fold peptides or PP-fold peptides mimics which have (i) a C-terminal Y receptor-recognition amino acid sequence represented by —X-Thr-Arg-X3-Arg-Tyr-C(=0)NR1R2 wherein R1 and R1 are independently hydrogen or C1-C6 alkyl X is Val, Ile, Leu or Ala, and X3 is Gln or Asn, or a conservatively substituted variant thereof in which Thr is replaced by His or Asn and / or Tyr is replaced by Trp or Phe; and / or Arg is replaced by Lys, and (ii) an N-terminal Y receptor-recognition amino acid sequence represented by H2N—X1-Pro-X2—(Glu or Asp)—wherein X1 is not present or is amino acid residue, and X2 is Leu or Ser or conservative substitutions of Leu or Ser, or (b) the said comprise a C-terminal Y receptor-recognition amino acid sequence as defined in (i) above, said Y receptor-recognition sequence being fused to an amphiphilic amino acid sequence domain comprising at least one alpha helical turn adjacent the N-terminus of the said hexapeptide sequence, said turn being constrained in a helical configuration by a covalent intramolecular link, and optionally an N-terminal sequence which commences with a Y receptor-recognition amino acid sequence as defined in (ii) above.

A computer implemented method, apparatus, and computer program product for determining the efficacy of neuropsychiatric therapy is provided. A neuroimage mapping manager automatically compares a first set of regions of interest in a first set of scans taken at a first time to a second set of regions of interest in a second set of scans generated at a second time and identifies a set of changes in the regions of interest occurring over time. The neuroimage mapping manager searches a set of electronic medical literature sources for medical literature relevant to the set of changes in the regions of interest and identifies portions of the relevant medical literature associated with the set of changes in the regions of interest. The neuroimage mapping manager generates results comprising the set of changes in the regions of interest and a set of links to the portions of the relevant medical literature.

A method for diagnosing and treating sleep disorders with a sleep therapy auto-titrator for in-home use by the patient includes the step of collecting, recording and analyzing sleep data in real time with the auto-titrator. Corrective action is provided in real time to the patient to mitigate sleep events based upon the collected sleep data. The collected sleep data is transmitted, via a global computer information system, to a remote server for storage. The stored sleep data is analyzed by a computer programmed with an algorithm to monitor therapy effectiveness daily and for identifying one or more therapy intervention recommendations. An alert is provided to at least one of the patient or a sleep therapy professional associated with the patient communicating the one or more intervention recommendations.

The present invention provides feline transplantable lung carcinoma xenografts and cell lines. Such xenografts and cell lines exhibit a number of unique characteristics which allows their use in experimental models of carcinoma in order to dissect out the molecular basis of this phenotype. This experimental model of carcinoma can be used to identify molecular targets for therapeutic intervention and to assess the efficacy of a broad spectrum of diagnostic and therapeutic agents. Specific animal models of lung cancer are described as well as methods for evaluating diagnostic and therapeutic agents for treating lung cancer.

An instrument for precisely cutting tissue to controlled dimensions (length, width, depth, and shape) is provided for the removal of tissue specimens from remote sites in the body of a patient, such as from the gastrointestinal tract, urinary tract, or vascular structures, or any tissue surface or soft tissue of the body. The instrument has a housing and a substantially flexible shaft extending from the housing to a distal end. The distal end of the instrument has an open cavity into which tissue is receivable. Suction can be communicated along the shaft to the distal end for distribution across the cavity utilizing a manifold having a grated tissue engaging surface with opening(s) for applying the suction, thereby pulling tissue adjacent to the distal end into the cavity against the tissue engaging surface of the manifold. One or more hollow needles are extendable from the housing through the shaft into the cavity to enable infusion of fluid, such as saline or a hemostatic agent, into the tissue. A blade in the distal end is extendable through the cavity over the manifold and across the opening to cut the tissue held by suction and stabilized by the needles in the cavity. The shape and depth of the tissue removed by the cuts is in accordance with the contour of the tissue engaging surface and the size and shape of the cavity at the distal end. The tissue so removed by the instrument may be for therapeutic intervention and / or represent a tissue specimen for biopsy suitable of diagnostic evaluation. The tissue edges in the patient's body left after cutting with this instrument readily avail themselves to apposition for enhanced healing.

The present invention provides methods and compositions for the identification and validation of biomarkers. The methods and compositions of the invention include the use of exogenous molecules specifically designed and chosen to be associated with a particular disease or biological process. Biomarkers identified and used according to the invention can be indicative of a number of biological processes, including disease state, response to a therapeutic intervention (such as pharmacological treatment, radiation therapy, chemotherapy, combination therapies, and the like), and responses to physiological challenges (such as aging, environmental toxins, etc.). Biomarkers identified through the methods and compositions of the invention may also serve as targets of therapeutic interventions.

The present invention relates to a system device and method for monitoring infant oral motor kinetics (OMK), which can be used to assess the functional significance of the different sucking components, i.e., the plasticity of infant sucking skills in relation to their oral feeding performance, at a particular time, during the developmental period and / or during preventive or therapeutic intervention programs. It is a unique system and apparatus that provides a means to study the nonnutritive and / or nutritive sucking skills, i.e., the Suction and / or Expression components of sucking, of infants in the natural setting, i.e., during a normal feeding session. OMK sensors, tracked in real-time by the monitoring system, include miniature pressure transducers, or pressure sensitive pads, attached to the nipple for measuring intraoral pressure pulses during Suction, and for measuring compression / stripping pressure pulses during Expression; and a miniature flow sensor for measuring fluid flow rate, which can be integrated over time to determine the volume of milk removed (bolus) per suck. Other signals, such as respiration, swallowing, thermal, optical, and acoustic signals can be recorded and compared along with the instrumented-nipple signals, in an OMK monitoring system.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PITX1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.

The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology.The biomarkers are selected from a first group consisting of Amy 1, Apo Al, Carbx, Casp, AFP, ApoM, SAP, Fib-a, Fib-b, Fib-g, ApoE, A2MG, A2MG isoform, Serpin, Clusterin, MHC-fB, SAP isoform, or from a second group consisting of Gpx3, properidin, MUP1, HMW-K, Lifr-p, Orm 1, MBL-A, MBP-C, wherein the biomarkers are regulated by EGF overexpression in a subject.

Occasionally relevant findings and important recommendations made within medical or radiology reports fail to elicit the appropriate follow-up due to multiple factors. The clinician may miss the recommendation or lose track of it while addressing a more acute illness, the recommendation may have not been conveyed to the patient, or the patient may fail to schedule or show-up for the subsequent exam. Prior literature indicates that a significant percentage of scheduled appointments result in no-shows or cancellations by patients, and a small but significant percentage of indicated follow-up studies are thus not obtained. Such omissions occasionally result in adverse consequences suffered by the patients, and increase the risk of legal liabilities to the clinicians or radiologists. A method and system is presented that identifies patients who did not obtain such recommended diagnostic tests or therapeutic interventions, and which sorts and filters the detected patients according to relevance of the recommendation, optionally discarding recommendations of low relevance, and facilitates the management of the detected patients.

Radiolabeled tracers for sodium / glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C1 preferred conformation, radio-labeled with 18F, 123I, or 124I, or free hexoses radiolabeled with 18F, 123I, or 124I. Also provided are in vivo and in vitro techniques for using these and other tracers as analytical and diagnostic tools to study glucose transport, in health and disease, and to evaluate therapeutic interventions.